

Podravka Group
business results
for 1 – 3 2024
UNAUDITED




1	KEY FINANCIAL INDICATORS IN 1 - 3 2024	3
2	SIGNIFICANT EVENTS IN 1 - 3 2024 AND AFTER THE BALANCE SHEET DATE	5
3	OVERVIEW OF SALES REVENUES IN 1 - 3 2024	11
4	PROFITABILITY IN 1 - 3 2024	18
5	KEY HIGHLIGHTS OF THE INCOME STATEMENT IN 1 - 3 2024	22
6	KEY HIGHLIGHTS OF THE BALANCE SHEET AS AT 31 MARCH 2024	25
7	KEY HIGHLIGHTS OF THE CASH FLOW STATEMENT IN 1 - 3 2024	28
8	SHARE IN 1 - 3 2024	31
9	ADDITIONAL TABLES FOR 1 - 3 2024	35
10	CONSOLIDATED FINANCIAL STATEMENTS IN 1 - 3 2024	38
11	STATEMENT OF RESPONSIBILITY	46
12	CONTACT	47



1

Key
financial
indicators
in 1 - 3 2024



KEY FINANCIAL INDICATORS IN 1 - 3 2024

NOTE: Decimal differences in the document are possible due to rounding.

(in EUR millions)	1 - 3 2023	1 - 3 2024	Δ	%
Sales revenue	175.9	191.8	15.9	9.1%
EBITDA ¹	27.3	37.9	10.6	38.8%
Net profit after MI	15.7	23.5	7.8	49.7%
Net cash flow from operating activities	30.9	26.2	(4.7)	(15.3%)
Cash capital expenditures	11.8	19.1	7.3	62.3%
Normalized EBITDA ²	27.6	38.0	10.4	37.9%
Normalized net profit after MI	15.9	23.6	7.7	48.3%
(in EUR; market capitalization in EURm)	31 Dec 2023	31 Mar 2024	Δ	%
Net debt / normalized EBITDA	0.2	0.1	(0.1)	(52.8%)
Normalized Earnings per share	6.7	7.8	1.1	15.9%
Last price at the end of period	163.0	160.0	(3.0)	(1.8%)
Market capitalization	1.143.6	1.126.2	(17.3)	(1.5%)
Return on average equity ³	8.8%	8.4%		-41 bp
Return on average assets ⁴	6.4%	6.2%		-23 bp

KEY HIGHLIGHTS IN 1 - 3 2024:

- In 1 - 3 2024, Podravka Group recorded a revenue increase of EUR 15.9m (+9.1%), where Food segment revenues increased by EUR 14.8m (+11.3%), while the Pharmaceuticals segment revenues grew by EUR 1.1m (+2.5%) relative to the comparative period,
- Operating profit before depreciation and amortisation (EBITDA) in 1 – 3 2024 amounted to EUR 37.9m, which is EUR 10.6m (+38.8%) higher than in the comparative period, while net profit after MI increased by EUR 7.8m (+49.7%). Normalized operating profit before depreciation and amortisation (EBITDA) amounted to EUR 38.0m and is higher than in the previous period by EUR 10.4m (+37.9%). The increase in normalized operating profit before depreciation and amortisation (EBITDA) was achieved due to higher sales revenues and higher gross profit, despite investments in improving the material status of employees in amount of EUR 4.6m (+13.0%). Normalized net profit after MI is EUR 7.7m (+48.3%) higher than in the comparative period.
- Total debt at the Podravka Group level increased by EUR 4.5m (+7.8%) due to the increase in liabilities for right-of-use assets by EUR 4.9m. At the end of the reporting period, net debt⁵ amounted to EUR 7.9m, which is EUR 7.0m (-46.8%) lower due to higher cash and cash equivalents, while the leverage (net debt to normalized EBITDA ratio) at the end of the reporting period stood at 0.1.

¹ Reported EBITDA is calculated in a way that EBIT was increased by the depreciation, amortisation and value adjustments of the non-current assets.

² Normalized EBITDA is calculated in a way that normalized EBIT was increased by the depreciation and amortization.

³ Normalized. Return on average equity is calculated in a way that normalized Net income is divided by average total shareholder's equity. Average total shareholder's equity is a sum of total shareholder's equity on the last day of reporting period (31.3.2024) and comparative period (31.12.2023) divided by 2. Normalized Net income include the last 12 months period.

⁴ Normalized. Return on average assets is calculated in a way that normalized Net income is divided by average total asset. Average total asset is a sum of total asset on the last day of reporting period (31.3.2024) and comparative period (31.12.2023) divided by 2. Normalized Net income include the last 12 months period.

⁵ Net debt= Financial debt – cash and cash equivalents



2

Significant
events in 1 - 3
2024 and after
the balance
sheet date



SIGNIFICANT EVENTS IN 1 - 3 2024 AND AFTER THE BALANCE SHEET DATE

NEW PODRAVKA GROUP CORPORATE LOGO PRESENTED

In order to further strengthen its presence on the global market and to ensure and support the achievement of strategic goals set by the business and sustainability strategy, Podravka redesigned its visual identity. The new visual identity is adapted to the new times and the needs and goals of the company, and for the first time the corporate logo of the Podravka Group is separated from the product logo of the Podravka brand. The new visual identity is based on the element of the heart and the red colour, it has preserved the most important and longest-lasting elements of the previous versions, thus preserving the company's recognizability and tradition. Also, this enables simpler and more effective communication with consumers and other stakeholders.

CEREMONIAL OPENING OF THE PODRAVKA PASTA FACTORY

The new Podravka Pasta Factory in Koprivnica was officially put into operation at the beginning of 2024. It is an investment worth more than 15 million euros, of which seven million euros were invested in construction infrastructure, and eight million euros in technology and assembly.

This investment is part of the investment cycle of the Podravka Group, which is carried out in accordance with the Group's Business Strategy until 2025. This is also the first newly built factory in the Food segment in the last 17 years. The pasta factory was built on more than 4,800 m². Inside the factory, there are two fully automated process lines for the production of short and curly pasta and three automated lines for packaging and palletizing the products. The new Pasta Factory produces industrial pasta that is used for the production of Podravka soups, as well as curly and short pasta under the Zlato Polje brand. The construction of the factory foresees the possibility of further expansion of technological capacities and product range, as well as further investment in renewable energy sources, i.e. a solar power plant. The construction of the factory and assembly of the lines ultimately took only one year, and with this investment, Podravka additionally ensures its own pasta production, modernizes the technological production process and further growth of the soup category, as well as the development of new products.

REALIZED INVESTMENTS AMOUNT TO ALMOST EUR 25 MILLION, TWICE AS MUCH AS IN THE SAME PERIOD LAST YEAR

The investment cycle of the Podravka Group is in full swing, and is carried out in accordance with the Podravka Group Business Strategy until 2025. Until the end of 2023, as part of the investment cycle that started in 2021, almost EUR 150m have been invested. During the first quarter of 2024, investments in the amount of almost EUR 25m were realized, which is twice as much as in the same period last year.

The priorities of the investment cycle are investment in modernization, the introduction of new technologies and digitization, raising effectiveness and energy efficiency, and further improving working conditions.

THE CONSTRUCTION OF A LOGISTICS AND DISTRIBUTION CENTRE in Koprivnica is the largest investment within the Podravka Group's Business Strategy until 2025, with the total value



of EUR 48m. The works began in March 2023 and their completion is expected in the second part of 2024. The logistics and distribution centre will meet the expected needs for storage space on the Croatian market in the next ten years, and if needed, it can be expanded in the future. With this investment, the Podravka Group will increase its efficiency in the logistics and distribution segment of operations through the optimization of the number of warehouses, minimization of internal transport and better cost control. This will also have a positive impact on the environment through the reduction of carbon dioxide emissions.

An investment in the MODERNIZATION AND INCREASE IN THE PRIMARY PROCESSING CAPACITY FOR FRESH TOMATOES in continental Croatia is underway, which includes the construction of a facility within the existing Kalnik factory in Varaždin. This will ensure the increase in the primary processing capacity for fresh tomatoes and continuity of own production, and the beginning of commercial production in the new facility is expected in the third quarter this year. In a broader sense, the investment also includes investment in AGRICULTURAL MACHINERY AND IRRIGATION, which is necessary for the smooth performance of primary production. For the needs of the new factory, Podravka will organize the production of tomatoes on its own land and with subcontractors, in total on approximately 400 hectares. Podravka will continue subcontractor production in Istria, but in order to meet the capacity of the new factory, it will also expand cooperation with subcontractors.

In the new Pasta factory, which was put into operation at the beginning of the year, investment in a LINE FOR THE PRODUCTION OF INSTANT NOODLES IS UNDERWAY. The investment will ensure own production, contribute to production efficiency and greater flexibility of production. The completion of the project is expected at the end of 2024, when the first own production will take place.

As part of the investment in energy sustainability and efficiency, the realization of the second phase of INVESTMENT IN SOLAR POWER PLANTS is underway, co-funded by the Modernisation fund – this is described in more detail in a separate chapter below.

In 2024, we continue with INVESTMENTS IN AGRICULTURAL MACHINERY and related equipment. The investment will result in savings in the costs of agrotechnical operations and provide the necessary raw materials for the new primary processing factory for fresh tomatoes in continental Croatia. We are also continuing to invest in the irrigation of agricultural lands – this is described in more detail in a separate chapter below.

The project is underway to BUILD A CENTRAL FACILITY FOR TRANSPORT AND MAINTENANCE WITH ACCOMPANYING FACILITIES, which will contribute to improving the working conditions of logistics employees and will make logistics processes more efficient. The main project has been prepared, and completion of works is expected in the third quarter of 2024.

A new IT SOLUTION FOR PLANNING AND REPORTING ON PROFITABILITY is being implemented. It is an investment that will enable further digitization of the planning process and reporting on the profitability of business segments and markets. By this, a higher level of flexibility will be achieved during the planning and reporting processes, and the processes will be largely automated. The completion of the project and use of the system is expected in the third quarter of 2024. The project of transitioning the existing SAP system to the SAP S/4HANA version is underway, which will improve operations and efficiency of business processes, primarily those in finance and accounting.



THE SECOND PHASE OF INVESTMENT IN SOLAR POWER PLANTS CO-FUNDED BY THE MODERNISATION FUND IS UNDERWAY

In accordance with the Sustainable Development Strategy, Podravka initiated projects to increase the share of renewable energy sources (as well as its own electricity production), and in 2023, the implementation of projects for the construction and equipping of the solar power plants Podravka Danica, Belupo – Danica, Cocktail and warehouse, Kalnik and Dugopolje began.

Five projects, including Belupo, were submitted to the Modernisation Fund competition, and all of them were positively evaluated. The total value is EUR 5,553,377.76, of which the support of the Modernisation Fund is 60% and amounts to EUR 3,330,106.66.

During October 2023, works began on all the above mentioned locations, the substructure was installed, most of the equipment was delivered (inverters, photovoltaic panels) and cable laying work is being carried out. The anticipated completion of the investments, with commissioning and obtaining all permits for permanent work, is October this year. Total installed power after the completion of the second phase will be 13.04 MW.

The next phase of the investment in solar power plants relates to the Pasta Factory and the new logistics and distribution center in Koprivnica, and the projects are expected to be completed in the second half of 2025. The investments will greatly contribute to the reduction of electricity costs.

For the implemented first phase of the project – the largest integrated solar power plant in Croatia, Podravka received the prestigious award of the Croatian Energy Society “Hrvoje Požar” last year in the category of the realized project of rational energy management and improvement of environmental quality.

PODRAVKA CONTINUES TO INVEST IN IRRIGATION SYSTEMS ON AGRICULTURAL LANDS

This year, Podravka continues to invest in the modernization of agricultural production, and one of the key goals is further investment in irrigation systems, i.e. the expansion of agricultural lands under irrigation. The project is co-financed by the European Union and the Republic of Croatia from the Rural Development Programme.

As part of Submeasure 4.1. “Support for investments in agricultural holdings” – implementation of operation type 4.1.1 “Restructuring, modernization and increasing the competitiveness of agricultural holdings” – investments in irrigation on agricultural holdings, Podravka was granted funds for the drip irrigation system in the amount of EUR 99,749.15. The plots are located on the territory of the municipalities of Hlebine and Koprivnički Bregi, and the total net area under the irrigation system is 63 ha.



Irrigation systems are a prerequisite for successful vegetable production, which strengthens the competitiveness of domestic agricultural production. With irrigation systems, we reduce the risk of the consequences of drought and contribute to a high and high-quality yield of agricultural crops, i.e. vegetables. Investing in irrigation will ensure greater quantities of high-quality raw materials for Podravka's factories, the production of raw materials of controlled origin ("from field to table"), reduce the need for imported raw materials, encourage domestic production, reduce the costs of producing finished products, and increase the yields of vegetables and other crops.

Podravka will continue to increase the production of its agricultural crops, as well as investments in irrigation systems and the modernization of agricultural production, with the aim of as efficient production as possible and increasing the quality and yield of agricultural products. All this will enable the security of supplying factories with high-quality raw materials, strengthening the leadership position and competitiveness and, ultimately, the satisfaction of end consumers.

NEW PRODUCT VEGETA FINE BLEND LAUNCHED

Vegeta is the best-selling dehydrated food seasoning in Europe⁶ and the leading brand on the market, which revolutionized the category of universal seasonings by adding pieces of vegetables, thus setting a standard that others continued to follow. We continuously monitor and listen to the needs of our consumers and introduce innovations – like Vegeta Fine blend, a food seasoning, but without visible pieces of vegetables – and it is a universal seasoning that does not exist on the market.

Vegeta Fine blend is unique, and the recipe and taste are the same as Vegeta Original. Ideal for all those dishes that require a smooth texture of seasonings, for example breading or marinating meat, tofu or vegetables and in various soups, sauces and dips.

PODRAVKA RECEIVED EQUAL PAY CHAMPION CERTIFICATE

Podravka includes professional equality and equal opportunities in all human resource management processes. The Equal Pay Champion certificate received confirmed that these are not just efforts, but that there are concrete results behind them. It is the first certificate in Croatia that is guided by the "Equal pay for equal work" principle, and it was launched with the aim of recognizing employers who are determined to achieve fairness and equality in their organization. The emphasis is on actively encouraging an inclusive organizational culture that provides equal opportunities for everyone.

In Podravka, with the introduction of the new salary system, a new basic salary was defined regardless of the gender of the executor, which had the effect of reducing the gender pay gap. Job applications are not defined by gender, and women and men are employed equally. Likewise, depending on their qualifications, they have equal opportunities for development and advancement. Additional competent female candidates are actively so

⁶ This statement and calculations are based on NIQ's data from the trade panel in thirty (30) European countries (Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, the Czech Republic, Denmark, Estonia, France, Greece, Croatia, Ireland, Italy, Latvia, Lithuania, the Netherlands, Norway, Germany, Hungary, Poland, Portugal, Romania, North Macedonia, Slovakia, Slovenia, Serbia, Spain, Sweden, Switzerland and Ukraine), according to which Vegeta is the leading brand in terms of volume sales in the dehydrated (dry) food seasonings category in the period October 2022 – September 2023 at the level of the total retail market in accordance with local definitions (copyright © 2023, Nielsen Consumer LLC, all rights reserved).



ught when managerial and professional positions are opened or for promotions. A positive example is the Management Board of Podravka Inc. where the share of women is 40%, which is already in line with the European Union Gender Equality Strategy until 2025.

Podravka is among 16 employers who received recognition for their work in reducing the gender pay gap and were declared leaders on this path. The Equal Pay Champion certificate is awarded by the SELECTIO Group, a leading group for consulting in human resources.

ČOKOLINO DARK AND VEGETA NATUR PASTY SEASONINGS DECLARED THE VOTED PRODUCTS OF THE YEAR 2024 IN CROATIA AND SLOVENIA

The voted product of the year is a renowned global award for marketing innovation voted by consumers, and the goal is to direct consumers to the best products and to reward manufacturers for quality and innovation. Consumers recognize the Voted Product of the Year sign on store shelves as a guarantee of excellence and trustworthy products.

PROPOSED DIVIDEND OF EUR 3.20 PER SHARE, 21% MORE THAN LAST YEAR

Based on the results achieved in 2023, the Management Board and the Supervisory Board proposed a dividend distribution of EUR 3.20 per share, which is 21% higher than last year. The amount of the dividend will be decided by the shareholders at the General Assembly of Podravka Inc. which will be held on 16th May 2024.

If the General Assembly adopts the Decision on the use of profit as proposed by the Management Board and the Supervisory Board, the dividend will be paid on 12th July 2024 to all shareholders registered in the depository of Central Depository and Clearing Company as at 14th June 2024.

Taking into account the last market price of the Podravka share at the end of 2023 (EUR 163.00), the proposed dividend amount implies a dividend yield of 2.0%. With the continuity of the dividend yield over the years, the Podravka Group confirms its focus on meeting the expectations set by shareholders



3

Overview of
sales revenues
in 1 - 3 2024



OVERVIEW OF SALES REVENUES IN 1 - 3 2024

SALES REVENUES BY SEGMENT IN 1 - 3 2024

(in EUR millions)	1 - 3 2023	1 - 3 2024	Δ	%
Food	131.7	146.5	14.8	11.3%
Own brands	123.7	134.6	10.9	8.8%
Other sales	8.0	11.9	3.9	48.9%
Pharmaceuticals	44.2	45.3	1.1	2.5%
Own brands	36.6	36.9	0.3	0.9%
Other sales	7.6	8.3	0.8	9.9%
Podravka Group	175.9	191.8	15.9	9.1%
Own brands	160.3	171.6	11.3	7.0%
Other sales	15.5	20.2	4.7	30.0%

MOVEMENTS OF THE FOOD SEGMENT REVENUES (1 - 3 2024 COMPARED TO 1 - 3 2023):

- OWN BRANDS recorded EUR 10.9m (+8.8%) higher sales due to the increase in sales of majority of business units,
- OTHER SALES recorded EUR 3.9m (+48.9%) higher sales, primarily as a result of the development of distribution on the US market,
- Overall, the Food segment recorded EUR 14.8m (+11.3%) higher sales.

MOVEMENTS OF THE PHARMACEUTICALS SEGMENT REVENUES (1 - 3 2024 COMPARED TO 1 - 3 2023):


- OWN BRANDS recorded EUR 0.3m (+0.9%) higher sales,
- OTHER SALES recorded EUR 0.8m (+9.9%) higher revenues, due to the increase in trade goods sales in the market of Bosnia and Herzegovina,
- Overall, the PHARMACEUTICALS SEGMENT recorded EUR 1.1m (+2.5%) higher sales revenues.

MOVEMENTS OF THE PODRAVKA GROUP REVENUES (1 - 3 2024 COMPARED TO 1 - 3 2023):

- Podravka Group's OWN BRANDS recorded an increase in sales of EUR 11.3m (+7.0%),
- The revenues of OTHER SALES are EUR 4.7m (+30.0%) higher,
- Overall, the PODRAVKA GROUP sales revenues are EUR 15.9m (+9.1%) higher.



SALES REVENUES BY SEGMENT IN 1 - 3 2024



SALES REVENUES BY BUSINESS UNITS AND CATEGORIES IN 1 - 3 2024

Sales revenues by business units and categories

(in EUR millions)	1 - 3 2023	1 - 3 2024	Δ	%
BU Culinary	25.6	31.3	5.7	22.3%
BU Soups	12.4	14.2	1.8	14.8%
BU Cereals, Snack and Beverages	11.5	12.9	1.3	11.6%
BU Creamy spreads and Desserts	10.4	12.4	2.0	19.2%
BU Bakery	17.8	17.5	(0.3)	(1.7%)
BU Fruits and Vegetables	15.2	16.5	1.2	8.1%
BU Basic food	15.1	13.0	(2.1)	(14.1%)
BU Meat products	8.6	9.9	1.3	15.0%
BU Fish	7.1	7.0	(0.1)	(0.9%)
Prescription drugs	29.9	29.4	(0.6)	(1.8%)
Non-prescription programme	6.7	7.6	0.9	13.5%
Other sales	15.5	20.2	4.7	30.0%
<i>Other sales Food</i>	<i>8.0</i>	<i>11.9</i>	<i>3.9</i>	<i>48.9%</i>
<i>Other sales Pharmaceuticals</i>	<i>7.6</i>	<i>8.3</i>	<i>0.8</i>	<i>9.9%</i>
Podravka Group	175.9	191.8	15.9	9.1%

NOTE: from 1st January 2024 as a result of internal reorganization, a part of assortment was separated from BU Basic food, and a new BU Fruit and Vegetables was created. Historical data have been adjusted to the new structure for comparability purposes.


MOVEMENTS OF SALES REVENUES BY BUSINESS UNITS AND CATEGORIES (1 - 3 2024 COMPARED TO 1 - 3 2023):

- THE CULINARY BUSINESS UNIT recorded EUR 5.7m (+22.3%) higher sales. Revenue growth was recorded mainly in the markets of Germany, Poland and Croatia. The revenue growth includes the effect of the restructuring of the markets of Poland and Germany, where higher revenues were recorded with a profitability increase,
- The SOUPS BUSINESS UNIT recorded EUR 1.8m (+14.8%) sales growth. The revenue growth of the business unit was realised in the key markets of the Southeastern Europe and Croatia. The Clear soups subcategory contributes most to a positive trend within the Soups business unit,
- The CEREALS, SNACK AND BEVERAGES BUSINESS UNIT recorded EUR 1.3m (+11.6%) higher sales. The sales revenue growth was recorded in almost all categories, primarily in the market of Croatia. The most significant growth within the business unit was recorded by the Cereals category, subcategory Čokolino,
- The CREAMY SPREADS AND DESSERTS BUSINESS UNIT records EUR 2.0m (+19.2%) higher sales. The revenue growth was recorded in the market of Croatia and in the Southeastern Europe region primarily due to the increase in the Creamy spreads category,
- The BAKERY BUSINESS UNIT recorded a mild revenue decrease of EUR 0.3m (-1.7%). Revenue growth was achieved in subcategories Bread, Sweet bakery products, and Cakes and biscuit cakes, while the decrease in revenues of the overall Business unit is primarily due to the Mill products category,
- The FRUIT AND VEGETABLES BUSINESS UNIT, separated from the Basic food business unit from the beginning of 2024, recorded an increase of EUR 1.2m (+8.1%), primarily due to the growth of categories Condiments, Processed fruit and Tomato products. The market of Croatia, which is the most significant market in the business unit portfolio, contributes most to the revenue growth,
- In the observed period, the BASIC FOOD BUSINESS UNIT recorded EUR 2.1m (-14.1%) lower sales, primarily in the Flour category, and subcategory Large packaging for industrial customers,
- In the reporting period, the MEAT PRODUCTS BUSINESS UNIT recorded EUR 1.3m (+15.0%) higher sales, primarily on the Croatian market. The revenue growth arises from the categories of Dried Meat and Sausage Products, and Ready meals,
- The FISH BUSINESS UNIT recorded EUR 0.1m (-0.9%) lower sales, which is primarily caused by the decline in revenues of the Tuna subcategory, while the new Fish salads category records a significant increase compared to the same period of the previous year,
- The PRESCRIPTION DRUGS CATEGORY recorded EUR 0.6m (-1.8%) lower sales, primarily due to the decrease in sales of the nervous system drugs, while the revenues of the most significant dermatological drugs category increase,



- The revenues of the **NON-PRESCRIPTION PROGRAMME CATEGORY** are EUR 0.9m (+13.5%) higher, as a result of the increase in sales of the OTC drugs subcategory,
- The **OTHER SALES CATEGORY** recorded EUR 4.7m (+30.0%) higher sales. In the Food segment, Other sales increased by EUR 3.9m (+48.9%), mainly due to the development of distribution on the US market which includes the revenues from the distribution of Atlantic Grupa's products. In the Pharmaceuticals segment, other sales grew by EUR 0.8m (+9.9%), primarily due to higher trade goods sales in the market of Bosnia and Herzegovina.

SALES REVENUES BY BUSINESS UNIT AND CATEGORY IN 1 - 3 2024



SALES REVENUES BY REGION IN 1 - 3 2024

Sales revenues by region


(in EUR millions)	1 - 3 2023	1 - 3 2024	Δ	%
Markets of Croatia and Slovenia	86.3	90.1	3.8	4.4%
Food	67.6	71.4	3.7	5.5%
Pharmaceuticals	18.6	18.7	0.0	0.2%
Southeastern Europe	38.6	42.8	4.3	11.1%
Food	26.2	29.0	2.7	10.4%
Pharmaceuticals	12.3	13.9	1.5	12.5%
WE and Overseas	18.2	26.4	8.2	44.7%
Food	18.0	26.1	8.0	44.4%
Pharmaceuticals	0.2	0.3	0.2	82.1%
Central Europe	21.1	21.5	0.4	2.1%
Food	18.2	18.4	0.1	0.7%
Pharmaceuticals	2.9	3.2	0.3	10.9%
Eastern Europe	11.7	11.0	(0.7)	(6.1%)
Food	1.5	1.8	0.2	14.8%
Pharmaceuticals	10.2	9.2	(0.9)	(9.3%)
Podravka Group	175.9	191.8	15.9	9.1%



MOVEMENTS OF SALES REVENUES BY REGION (1 - 3 2024 COMPARED TO 1 - 3 2023):


- The **MARKETS OF CROATIA AND SLOVENIA** recorded a sales increase of EUR 3.8m (+4.4%). Food segment revenues increased by EUR 3.7m (+5.5%), due to sales increase of almost all business units, mostly the Business unit Fruit and vegetables, Business unit Meat products and Business unit Creamy spreads and Desserts. In the market of Croatia and Slovenia, the Retail sales channel achieved the strongest revenue growth. Pharmaceuticals segment revenues in the Market of Croatia and Slovenia are at the last-year's levels,
- Revenues of the **SOUTHEASTERN EUROPE REGION** grew by EUR 4.3m (+11.1%) in the reporting period. The Food segment recorded revenue growth of EUR 2.7m (+10.4%), due to the increase in sales of almost all business units, with the largest absolute growth generated by the business units Culinary and Soups. Pharmaceuticals segment revenues are EUR 1.5m higher (+12.5%), primarily due to Prescription drugs and Non-prescription programme sales increase,
- The **WESTERN EUROPE AND OVERSEAS** region recorded EUR 8.2m (+44.7%) higher sales. The Food segment recorded EUR 8.0m (+44.4%) higher sales primarily due to the sales increase in the Culinary business unit, but also to the development of distribution on the US market. The Pharmaceuticals segment revenues are EUR 0.2m (+82.1%) higher, primarily due to an increase in Prescription drugs revenues,
- The revenues of **CENTRAL EUROPE** in the reporting period are higher by EUR 0.4m (+2.1%). In the Food segment, a mild increase in revenue of EUR 0.1m (0.7%) was recorded, primarily as a result of an increase in revenues of the Culinary business unit in the market of Poland, which is a result of the previously implemented market restructuring. In the Pharmaceuticals segment, revenue growth of EUR 0.3m (+10.9%) was achieved due to higher revenues of the Prescription drugs category,
- The **EASTERN EUROPE REGION** recorded a decrease in revenues of EUR 0.7m (-6.1%), as a result of the decrease in sales of the Pharmaceuticals segment of EUR 0.9m (-9.3%) due to the decrease in sales of the Prescription drugs category. The Food segment recorded EUR 0.2m (+14.8%) higher revenues.

SALES REVENUES BY REGION
IN 1 - 3 2024



4

Profitability in 1 - 3 2024



PROFITABILITY IN 1 - 3 2024

NOTE: The overview and explanation of items treated as one-off by management and the overview of methodology of calculation of the normalized result are provided in the "Additional tables for 1 - 3 2024" section.

PROFITABILITY OF THE FOOD SEGMENT IN 1 - 3 2024

(in EUR millions)	Profitability of the Food segment				Normalized			
	1 - 3 2023	1 - 3 2024	Δ	%	1 - 3 2023	1 - 3 2024	Δ	%
Sales revenue	131.7	146.5	14.8	11.3%	131.7	146.5	14.8	11.3%
Gross profit	40.3	53.2	12.9	32.0%	40.3	53.3	12.9	32.0%
EBITDA*	14.5	23.9	9.4	64.8%	14.8	24.1	9.3	62.6%
EBIT	8.8	17.8	9.0	101.2%	9.1	18.0	8.8	96.5%
Net profit after MI	7.4	14.5	7.0	95.0%	7.7	14.6	6.9	90.6%
Gross margin	30.6%	36.3%		+570 bp	30.6%	36.4%		+572 bp
EBITDA margin	11.0%	16.3%		+529 bp	11.2%	16.4%		+518 bp
EBIT margin	6.7%	12.1%		+543 bp	6.9%	12.3%		+532 bp
Net margin after MI	5.6%	9.9%		+424 bp	5.8%	10.0%		+414 bp

* EBITDA is calculated in a way that EBIT was increased by depreciation and amortization and value adjustments of non-current assets; normalized EBITDA is calculated in a way that normalized EBIT was increased by depreciation and amortization.

PROFITABILITY OF THE FOOD SEGMENT (1 - 3 2024 COMPARED TO 1 - 3 2023):

- In the 1 - 3 2024 period, the Food segment recorded an increase in GROSS PROFIT of EUR 12.9m (+32.0%) with an increase in gross margin from 30.6% to 36.3%. OPERATING PROFIT BEFORE DEPRECIATION AND AMORTISATION (EBITDA) is EUR 9.4m (+64.8%) higher, while NORMALISED OPERATING PROFIT BEFORE DEPRECIATION AND AMORTISATION (EBITDA) is EUR 9.3m (+62.6%) higher,
- The increase in the NORMALIZED OPERATING PROFIT BEFORE DEPRECIATION and amortisation (EBITDA) was achieved due to the increase in sales revenues and higher gross profit, despite additional investments in improving the material status of employees, which resulted in an increase in staff costs of EUR 3.7m (+13.6%).
- NET PROFIT AFTER MINORITY INTERESTS is EUR 7.0m higher (+95.0%) due to the above mentioned effects on profitability, while at the normalized level it is higher by EUR 6.9m (+90.6%).



PROFITABILITY OF THE PHARMACEUTICALS SEGMENT IN 1 - 3 2024

(in EUR millions)	Profitability of the Pharmaceutical segment				Normalized			
	1 - 3 2023	1 - 3 2024	Δ	%	1 - 3 2023	1 - 3 2024	Δ	%
Sales revenue	44.2	45.3	1.1	2.5%	44.2	45.3	1.1	2.5%
Gross profit	22.2	23.4	1.2	5.2%	22.2	23.4	1.2	5.2%
EBITDA*	12.8	14.0	1.2	9.3%	12.8	14.0	1.2	9.3%
EBIT	10.6	11.7	1.1	10.7%	10.6	11.7	1.1	10.7%
Net profit after MI	8.3	9.0	0.7	9.1%	8.3	9.0	0.7	9.1%
Gross margin	50.3%	51.6%		+133 bp	50.3%	51.6%		+133 bp
EBITDA margin	29.0%	30.9%		+192 bp	29.0%	30.9%		+192 bp
EBIT margin	24.0%	25.9%		+192 bp	24.0%	25.9%		+192 bp
Net margin after MI	18.7%	19.9%		+120 bp	18.7%	19.9%		+120 bp

* EBITDA is calculated in a way that EBIT was increased by depreciation and amortization and value adjustments of non-current assets; normalized EBITDA is calculated in a way that normalized EBIT was increased by depreciation and amortization.

PROFITABILITY OF THE PHARMACEUTICALS SEGMENT (1 - 3 2024 COMPARED TO 1 - 3 2023):

- The Pharmaceuticals segment recorded EUR 1.2m (+5.2%) higher GROSS PROFIT, with a mild increase in gross margin,
- OPERATING PROFIT BEFORE DEPRECIATION AND AMORTISATION (EBITDA) is higher by EUR 1.2m (+9.3%). The most significant impact on the increase in operating profit before depreciation and amortisation (EBITDA) came from the growth of sales revenues and gross profit. In the reporting period, there were no normalizations of one-off items within Pharmaceuticals,
- NET PROFIT AFTER MINORITY INTERESTS is EUR 0.7m (+9.1%) higher.



PROFITABILITY OF THE PODRAVKA GROUP IN 1 - 3 2024

(in EUR millions)	Profitability of the Podravka Group				Normalized			
	1 - 3 2023	1 - 3 2024	Δ	%	1 - 3 2023	1 - 3 2024	Δ	%
Sales revenue	175.9	191.8	15.9	9.1%	175.9	191.8	15.9	9.1%
Gross profit	62.5	76.6	14.0	22.5%	62.5	76.6	14.1	22.5%
EBITDA*	27.3	37.9	10.6	38.8%	27.6	38.0	10.4	37.9%
EBIT	19.4	29.5	10.1	51.9%	19.7	29.7	10.0	50.5%
Net profit after MI	15.7	23.5	7.8	49.7%	15.9	23.6	7.7	48.3%
Gross margin	35.6%	39.9%		+437 bp	35.6%	40.0%		+439 bp
EBITDA margin	15.5%	19.7%		+423 bp	15.7%	19.8%		+414 bp
EBIT margin	11.0%	15.4%		+434 bp	11.2%	15.5%		+426 bp
Net margin after MI	8.9%	12.2%		+332 bp	9.0%	12.3%		+325 bp

* EBITDA is calculated in a way that EBIT was increased by depreciation and amortization and value adjustments of non-current assets; normalized EBITDA is calculated in a way that normalized EBIT was increased by depreciation and amortization.

PROFITABILITY OF THE PODRAVKA GROUP (1 - 3 2024 COMPARED TO 1 - 3 2023):

- In the observed period, the Podravka Group recorded EUR 14.0m (+22.5%) higher GROSS PROFIT with an increase in gross margin, where the positive impact came primarily from the Food segment, but also from the Pharmaceuticals segment,
- OPERATING PROFIT BEFORE DEPRECIATION AND AMORTISATION (EBITDA) is EUR 10.6m (+38.8%) higher, while NORMALISED OPERATING PROFIT BEFORE DEPRECIATION AND AMORTISATION (EBITDA) is EUR 10.4m (+37.9%) higher,
- NET PROFIT AFTER MINORITY INTERESTS is EUR 7.8m higher (+49.7%). NORMALIZED NET PROFIT AFTER MINORITY INTERESTS is EUR 7.7m (+48.3%) higher, due to the growth in net profit of both the Food and the Pharmaceuticals segments.



5

Key highlights
of the income
statement in
1 - 3 2024



KEY HIGHLIGHTS OF THE INCOME STATEMENT IN 1 - 3 2024

PODRAVKA GROUP (in EUR millions)	REPORTED				NORMALIZED			
	1 - 3 2023	1 - 3 2024	Δ	%	1 - 3 2023	1 - 3 2024	Δ	%
Cost of goods sold	113.3	115.2	1.9	1.7%	113.3	115.2	1.8	1.6%
General and administrative expenses	12.0	13.1	1.2	9.8%	11.7	13.0	1.3	11.1%
Selling and distribution costs	21.7	23.0	1.4	6.3%	21.7	23.0	1.4	6.3%
Marketing expenses	9.5	11.1	1.6	16.6%	9.5	11.1	1.6	16.6%
Other expenses (income), net	(0.1)	(0.2)	(0.1)	258.9%	(0.0)	(0.2)	(0.1)	271.1%
Total operating expenses	156.4	162.3	5.8	3.7%	156.1	162.1	6.0	3.8%

COST OF GOODS SOLD

Cost of goods sold increased by 1.7% relative to the comparative period, primarily as a result of investments in improving the material status of employees, while the prices of raw materials, packaging and energy record a decrease compared to the first quarter of the previous year.

GENERAL AND ADMINISTRATIVE EXPENSES

In relation to the comparative period, general and administrative expenses are EUR 1.2m higher (+9.8%), primarily due to investments in improving the material status of employees.

SELLING AND DISTRIBUTION COSTS

In the observed period, selling and distribution costs are EUR 1.4m (+6.3%) higher than in the comparative period, primarily as a result of investments in improving the material status of employees and higher depreciation costs.

MARKETING EXPENSES

In the reporting period, marketing expenses (which include marketing investments expenses and marketing department expenses) are 16.6% higher than in the comparative period. In this, the costs of marketing investments are higher by EUR 1.5m (+36.0%) due to the increased marketing activities, while the costs of the marketing department are higher by EUR 0.1m (+1.5%).



OTHER EXPENSES (INCOME), NET

In the reporting period, other expenses and income, net amounted to EUR -0.2m (positive impact), while in the comparative period they amounted to EUR -0.1m (positive impact). This was mainly affected by lower foreign exchange losses, which in 1 - 3 2024 amounted to EUR 0.2m, while in the previous period foreign exchange losses amounted to EUR 0.4m

NET FINANCE COSTS

In the observed period, net finance costs amounted to EUR 0.3m (negative impact), and they are at the same levels as in the same period of the previous year.

INCOME TAX

The reported income tax of the Podravka Group in 1 – 3 2024 amounted to EUR -5.2m, while in the same period of the previous year it amounted to EUR -3.1m, due to the higher EBT base.



6

Key highlights
of the balance
sheet as at 31
March 2024



KEY HIGHLIGHTS OF THE BALANCE SHEET AS AT 31 MARCH 2024

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment of the Podravka Group are EUR 11.0m or +3.2% higher compared to 31 December 2023, due to the realized capital investments implemented within the strong investment cycle on the basis of the adopted Business Strategy.

INVENTORIES

Inventories of the Podravka Group are EUR 4.7m (+3.1%) higher than as at 31 December 2023 and are maintained at the optimum level in accordance with the needs of operations. Compared to 31 March 2023, inventories are lower by EUR 10.4m (-6.3%).

TRADE AND OTHER RECEIVABLES

Trade and other receivables of the Podravka Group are EUR 9.6m (+7.5%) higher than as at 31 December 2023 primarily as a result of the increase in sales revenues in the reporting period. Compared to 31 March 2023, receivables are higher by EUR 13.3m (+10.6%), due to growth in sales revenue and a change in the commercial model in the Pharmaceuticals segment on the Croatian market.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents of the Podravka Group at the end of the observed period are EUR 11.5m higher (+27.0%) compared to 31 December 2023. This is explained in the “Key highlights of the cash flow statement in 1 – 3 2024” section.

LONG-TERM AND SHORT-TERM BORROWINGS

As at 31 March 2024, long-term and short-term borrowings of the Podravka Group amounted to EUR 43.6m and are EUR 0.4m lower than as at 31 December 2023 as a result of regular repayment of borrowings. Considering the strong cash flow from operating activities, the continuous deleveraging is carried out with simultaneous strong investments in the investment cycle.

TRADE AND OTHER PAYABLES

Trade and other payables of the Podravka Group are EUR 4.5m (or +3.9%) higher compared to 31 December 2023, while they are EUR 16.3m (+15.4%) higher compared to 31 March 2023.


This movement is a result of higher liabilities related to the realization of capital investments, and regular business operations.



INDEBTEDNESS

As at 31 March 2024, the total debt of the Podravka Group related to borrowings and other interest-bearing financial liabilities amounted to EUR 61.9m, of which EUR 0.4m relates to long-term borrowings, EUR 43.2m to short-term borrowings, while EUR 18.3m relates to liabilities for right-of-use assets. The AVERAGE WEIGHTED COST OF DEBT on all the stated liabilities as at 31 March 2024 was 0.8%, while if right-of-use assets are excluded it was 1.5%.

CURRENCY STRUCTURE OF DEBT AS AT 31 MARCH 2024



Analysing the debt currency structure, the highest exposure, of 96.2%, was in the Euro (EUR). The debt share in the Bosnia and Herzegovina mark (BAM) amounted to 1.9%, in the Czech koruna (CZK) to 0.5%, while the remainder of 1.4% relates to other currencies.

(in EUR millions)*	2023	1 - 3 2024	Δ	%
Financial debt ⁷	57.4	61.9	4.5	7.8%
Cash and cash equivalents	42.5	54.0	11.5	27.0%
Net debt ⁸	14.9	7.9	(7.0)	(46.8%)
Interest expense	0.68	0.70	0.0	2.6%
Net debt / normalized EBITDA	0.18	0.08	(0.1)	(52.8%)
Normalized EBIT / Interest expense	87.3	99.2	11.9	13.7%
Equity to assets ratio ⁹	73.9%	73.6%		-32 bb

* NOTE: all indicators are calculated in a way that income statement items are calculated at the level of the last 12 months, while balance sheet items are taken at the period end.

Net debt decrease as at 31 March 2024 compared to 31 December 2023 is the result of an increase in the line item cash and cash equivalents of EUR 11.5m. The increase in normalized EBITDA and the decrease in net debt led to a lower net debt to normalized EBITDA ratio. The increase in normalized EBIT has driven the rise in the interest coverage ratio (Normalized EBIT / Interest expense).


⁷ Financial debt: long-term and short-term borrowings + lease liabilities + financial liabilities at fair value through profit or loss. The data is provided in the "Consolidated statements of financial position as at 31 March 2024" section.

⁸ Net debt: Financial debt – Cash and cash equivalents.

⁹ Equity to assets ratio: total shareholder's equity / total assets. The data is provided in the "Consolidated statements of financial position as at 31 March 2024" section.

7

Key highlights
of the cash flow
statement in
1 - 3 2024



KEY HIGHLIGHTS OF THE CASH FLOW STATEMENT IN 1 - 3 2024

(in EUR millions)	1 - 3 2023	1 - 3 2024	Δ
Net cash flow from operating activities	30.9	26.2	(15.3%)
Net cash flow from investing activities	(11.5)	(10.8)	6.5%
Net cash flow from financing activities	0.1	(3.9)	n/a
Net increase / (decrease) of cash and cash equivalents	19.5	11.5	(41.1%)

NET CASH FLOW FROM OPERATING ACTIVITIES

In the observed period, net cash flow from operating activities amounted to positive EUR 26.2m as a result of operating business and dynamics of movements in the working capital.

NET CASH FLOW FROM INVESTING ACTIVITIES

Net cash flow from investing activities in the reporting period amounted to negative EUR 10.8m, primarily due to cash capital expenditures in the amount of EUR 19.1m.

The most significant capital expenditures in 1 - 3 2024 were related to:

- Continued investment activities related to the investment in the construction of a new logistics and distribution centre with the aim of increasing efficiency in the logistics and distribution segment of business through optimization of the number of warehouse spaces, minimization of internal transport, greater control of costs and reduction of carbon dioxide emissions. Investment activities in the first quarter of 2024 marked the continuation of construction works, the installation of racks in the high-bay warehouse and the beginning of the installation of technological equipment,
- Continued investment activities related to the bakery concentration project in order to improve production efficiency and reduce operating expenses. The investment activities in the first quarter of 2024 marked the continuation of investments in production equipment, assembly of the received equipment and the expansion of the existing shipping area,
- Continued investment activities related to the construction of the new tomato factory in continental Croatia. During the first quarter of 2024, technology and production equipment were installed,
- Start of investment activities related to the 2nd and 3rd phases of investment in agricultural machinery and irrigation systems with the aim of securing own raw materials and better soil cultivation. The investment will also result in reduced costs of agrotechnical operations,
- Continued investment activities in the line for the production of instant noodles, which will ensure the appropriate level of quality through the management of own production (“insourcing”). During the first quarter of 2024, tenders for technological equipment were carried out and technological trials of recipe development were carried out at the supplier of the process line,



- Start of investment activities related to the construction of a central facility for transportation and maintenance with accompanying facilities. The investment will contribute to improving working conditions and increasing the efficiency of logistics processes,
- The final phase of investment activities related to the modernization of the truck fleet aimed at reducing maintenance costs and improving the efficiency, timeliness and reliability of transport and distribution,
- Start of investment activities related to the purchase of forklifts with the aim of reducing maintenance costs, increasing timeliness, quality and reliability of delivery,
- Continued investment activities related to the investment in additional solar power plants and reconstruction of the thermal energy production and supply system that will reduce energy consumption. During the first quarter of 2024, most of the solar panels and inverters were installed,
- Continued investment activities related to the production digitization project of other factories in order to improve production efficiency and reduce operating expenses,
- Continued investment activities related to investment in IT technologies for planning and profitability. During the first quarter of 2024, the design of the desired state of the system was defined. The goal of IT technologies for planning and profitability is to improve business processes, which will result in a reduction in time and a higher level of automation and flexibility.

The above capital expenditures are expected to positively impact the operating profitability increase. In 2024, expected capital expenditures are at a level of almost EUR 90.5m.


NET CASH FLOW FROM FINANCING ACTIVITIES

In the 1 - 3 2024 period, net cash flow from financing activities amounted to negative EUR 3.9m primarily due to the repayment of lease liabilities and purchase of treasury shares.



8

Share in
1 - 3 2024



SHARE IN 1 - 3 2024


LIST OF MAJOR SHAREHOLDERS AS AT 31 MARCH 2024

No.	Shareholder	Number of shares	% ownership
1.	PBZ Croatia Osiguranje mandatory pension fund, category B	1,097,644	15.4%
2.	AZ mandatory pension fund, category B	932,563	13.1%
3.	RSC* - Croatian Pension Insurance Institute	727,703	10.2%
4.	Erste Plavi mandatory pension fund, category B	638,248	9.0%
5.	Raiffeisen mandatory pension fund, category B	625,298	8.8%
6.	RSC* - Republic of Croatia	452,792	6.4%
7.	Capital Fund	406,842	5.7%
8.	Pivac Brothers Meat Industry	370,977	5.2%
9.	Republic of Croatia	167,281	2.3%
10.	OTP banka D.D./aggregate custody accounts	97,035	1.4%
	Other shareholders	1,603,620	22.5%
	Total	7,120,003	100.0%

* The Restructuring and Sale Centre holds 1,241,504 shares through four accounts, Capital Fund Inc. holds 406,842 shares, the Republic of Croatia additionally holds 167,281 shares on a separate account.

Podravka Inc. has a stable ownership structure where the most significant stake is held by the Republic of Croatia and domestic pension funds. A total of 7,120,003 shares have been issued at nominal price of EUR 30.0 per share. As at 31 March 2024, the Republic of Croatia holds 25.5% stake, and domestic pension funds (mandatory and voluntary) hold a total of 50.1% stake. Podravka Inc. has 1.3% of treasury shares. Podravka Inc.'s shares have been listed on the Prime Market of the Zagreb Stock Exchange and in eight Zagreb Stock Exchange indices (CROBEX, CROBEX10, CROBEXtr, CROBEX10tr, CROBEXprime, CROBEXplus, CROBEXnutris and ADRIAprime).


OWNERSHIP STRUCTURE AS AT 31 MARCH 2024



** Includes all mandatory and voluntary pension funds managed by the pension companies: AZ, ROMF, PBZCO and ERSTE.



SHARE PRICE MOVEMENT IN 1 - 3 2024



(closing price in EUR; closing points)	31 December 2023	31 March 2024	%
PODR	163.0	160.0	(1.8%)
CROBEX	2,533.9	2,834.5	11.9%
CROBEX10	1,548.6	1,713.2	10.6%

In the reporting period, the Podravka's share decreased by 1.8% compared to the end of 2023. At the same time, the stock indices grew, where CROBEX increased by 11.9%, while CROBEX10 increased by 10.6%.

RESULT ON THE CROATIAN CAPITAL MARKET IN 1 - 3 2024

(in EUR; in units) ¹⁰	1 - 3 2023	1 - 3 2024	%
Weighted average daily price	92.8	163.6	76.2%
Average daily number of transactions	10	12	21.3%
Average daily volume	729	770	5.6%
Average daily turnover	66,628.0	125,954.0	89.0%

In the 1 - 3 2024 period, the weighted average daily price of Podravka's share recorded an increase of 76.2% relative to the comparative period. Compared to 1 - 3 2023, the average daily number of transactions is 21.3% higher, the average daily volume increased by 5.6%, and the average daily turnover increased by 89.0%.

¹⁰ The weighted average daily price in the reporting period is calculated as the sum of the weighted average daily prices in the reporting period, multiplied by the daily volume weight. The daily volume weight is calculated as a ratio of daily volume and total volume in the reporting period. The formula, Weighted average daily price in the reporting period = \sum average daily price*(daily volume/total volume in the reporting period).

Other indicators are calculated as the average of average daily transactions/volume/turnover in the reporting period. Block trades are excluded from the calculation.



VALUATION

(in EUR millions; last price and earnings per share in EUR)*	2023	1 - 3 2024	%
Last price	163.0	160.0	(1.8%)
Weighted average number of shares ¹¹	7,015,732	7,038,968	0.3%
Market capitalization ¹²	1,143.6	1,126.2	(1.5%)
EV ¹³	1,169.1	1,144.5	(2.1%)
Normalized earnings per share ¹⁴	6.7	7.8	15.9%
EV / sales revenue	1.6	1.6	(4.2%)
EV / normalized EBITDA	12.7	12.2	(4.0%)
EV / normalized EBIT	19.6	16.4	(16.1%)
Last price / normalized earnings per share ratio (P / E)	24.2	20.5	(15.3%)

* Note: all indicators are calculated in a way that income statement items are calculated at the level of the last 12 months, while balance sheet items are taken at the period end.

¹¹ The weighted average number of shares is calculated on the basis of previous 12 months period by dividing the sum of the weighted number of shares of each individual month by the total number of calendar days in the previous 12 months. The weighted number of shares on a monthly basis is calculated by reducing the total number of issued shares by the amount of treasury shares and multiplying the difference by the number of days of that month.

¹² Market Capitalization: Last price * Weighted average number of shares.

¹³ Enterprise value: Market Capitalization + Net debt + Minority interests.

¹⁴ Normalized earnings per share is calculated in a way that normalized Net income after minority interests is divided with weighted average number of shares. Normalized Net income after minority interests include the last 12 months period.



9

Additional
tables for
1 - 3 2024



ADDITIONAL TABLES FOR 1 - 3 2024

CALCULATION OF REPORTED AND NORMALIZED EBITDA

EBITDA is calculated in a way that EBIT was increased by depreciation and amortization and value adjustments to non-current assets. Value adjustments to non-current assets in the reporting and the comparative periods are presented in the table below.

Reported EBITDA calculation		1 - 3 2023			1 - 3 2024		
(in EUR millions)	Group	Food	Pharma	Group	Food	Pharma	
Reported EBIT	19.43	8.84	10.58	29.52	17.80	11.72	
+amortization and depreciation	7.86	5.66	2.21	8.35	6.09	2.26	
+value adjustments	-	-	-	-	-	-	
Reported EBITDA	27.29	14.50	12.79	37.87	23.89	13.98	

Normalized EBITDA calculation		1 - 3 2023			1 - 3 2024		
(in EUR millions)	Group	Food	Pharma	Group	Food	Pharma	
Normalized EBIT	19.73	9.14	10.58	29.69	17.97	11.72	
+amortization and depreciation	7.86	5.66	2.21	8.35	6.09	2.26	
+value adjustments	-	-	-	-	-	-	
Normalized EBITDA	27.59	14.80	12.79	38.04	24.06	13.98	



ONE-OFF ITEMS IN 1 - 3 2024 AND 1 - 3 2023

In the 1 - 3 2024 period, the Food segment incurred EUR 0.12m costs of severance payments for employees, EUR 0.11m of costs related to the restructuring of the Žito Group, and income from the sale of non-operating assets of EUR 0.05m.

In the Pharmaceuticals segment, there were no one-off items.

The estimated impact of these one-off items on tax of the Food segment is EUR 0.03m (decreases it).

In the 1 - 3 2023 period, the Food segment incurred EUR 0.3m costs of severance payments for employees (long-term sick leaves and the restructuring of the Žito Group) and EUR 0.02m of income from the sale of assets, also related to the restructuring of the Žito Group.

In the Pharmaceuticals segment, there were no one-off items.

The estimated impact of these one-off items on tax of the Food segment is EUR 0.06m (decreases it).

NORMALIZATION OF THE PROFIT AND LOSS STATEMENT BY SEGMENTS

Reported and normalized profitability	1 - 3 2023			1 - 3 2024		
(in EUR millions)	Group	Food	Pharma	Group	Food	Pharma
Reported gross profit	62.55	40.34	22.21	76.60	53.23	23.36
+cost of restructuring Žito group	-	-	-	0.03	0.03	-
Normalized gross profit	62.55	40.34	22.21	76.63	53.26	23.36
Reported EBITDA	27.29	14.50	12.79	37.87	23.89	13.98
+severance payments	0.32	0.32	-	0.12	0.12	-
+income from the sale of other asset	(0.02)	(0.02)	-	(0.05)	(0.05)	-
+cost of restructuring Žito group	-	-	-	0.08	0.08	-
Normalized EBITDA	27.59	14.80	12.79	38.04	24.06	13.98
Reported EBIT	19.43	8.84	10.58	29.52	17.80	11.72
+normalizations above EBITDA level	0.30	0.30	-	0.17	0.17	-
Normalized EBIT	19.73	9.14	10.58	29.69	17.97	11.72
Reported Net profit after MI	15.67	7.41	8.25	23.45	14.45	9.00
+normalizations above EBIT level	0.30	0.30	-	0.17	0.17	-
+estimated impact of normalization on taxes	(0.06)	(0.06)	-	(0.03)	(0.03)	-
Normalized Net profit after MI	15.91	7.65	8.25	23.59	14.59	9.00



10

Consolidated
financial
statements in
1 - 3 2024



CONSOLIDATED FINANCIAL STATEMENTS IN 1 - 3 2024

CONSOLIDATED PROFIT AND LOSS STATEMENT IN 1 - 3 2024

(in EUR thousands)	1 - 3 2023	% of sales revenues	1 - 3 2024	% of sales revenues	%change
Sales revenue	175,860	100.0%	191,781	100.0%	9.1%
Cost of goods sold	(113,310)	(64.4%)	(115,184)	(60.1%)	1.7%
Gross profit	62,549	35.6%	76,597	39.9%	22.5%
General and administrative expenses	(11,972)	(6.8%)	(13,147)	(6.9%)	9.8%
Selling and distribution costs	(21,689)	(12.3%)	(23,047)	(12.0%)	6.3%
Marketing expenses	(9,520)	(5.4%)	(11,095)	(5.8%)	16.6%
Other (expenses) / income, net	58	0.0%	207	0.1%	258.9%
Operating profit	19,427	11.0%	29,515	15.4%	51.9%
Financial income	90	0.1%	312	0.2%	247.1%
Other financial expenses	(182)	(0.1%)	(370)	(0.2%)	102.7%
Interest expenses	(189)	(0.1%)	(207)	(0.1%)	9.5%
Net foreign exchange differences on borrowings	(6)	(0.0%)	(46)	(0.0%)	652.5%
Net finance costs	(288)	(0.2%)	(311)	(0.2%)	8.1%
Profit before tax	19,139	10.9%	29,204	15.2%	52.6%
Current income tax	(1,599)	(0.9%)	(2,862)	(1.5%)	79.0%
Deferred tax	(1,539)	(0.9%)	(2,324)	(1.2%)	51.0%
Income tax	(3,138)	(1.8%)	(5,187)	(2.7%)	65.3%
Net profit for the year	16,001	9.1%	24,017	12.5%	50.1%
Net profit / (loss) attributable to:					
Equity holders of the parent	15,666	8.9%	23,454	12.2%	49.7%
Non-controlling interests	335	0.2%	564	0.3%	(68.3%)



CONSOLIDATED BALANCE SHEET AS AT 31 MARCH 2024

(in EUR thousands)	31 Dec 2023	% share	31 Mar 2024	% share	% change
ASSETS					
Non-current assets					
Goodwill	3,776	0.5%	3,776	0.5%	0.0%
Intangible assets	33,439	4.3%	34,627	4.3%	3.6%
Property, plant and equipment	342,366	44.0%	353,412	43.6%	3.2%
Right-of-use assets	13,200	1.7%	18,029	2.2%	36.6%
Investment property	13,819	1.8%	13,770	1.7%	(0.4%)
Non-current financial assets	5,734	0.7%	5,822	0.7%	1.5%
Deferred tax assets	25,385	3.3%	23,039	2.8%	(9.2%)
Total non-current assets	437,719	56.3%	452,475	55.8%	3.4%
Current assets					
Inventories	150,826	19.4%	155,493	19.2%	3.1%
Trade and other receivables	128,255	16.5%	137,902	17.0%	7.5%
Financial assets at fair value through profit and loss	59	0.0%	0	0.0%	(100.0%)
Debit securities at amortized cost	7,957	1.0%	0	0.0%	(100.0%)
Income tax receivable	3,292	0.4%	3,378	0.4%	2.6%
Cash and cash equivalents	42,528	5.5%	54,015	6.7%	27.0%
Non-current assets held for sale	7,434	1.0%	7,471	0.9%	0.5%
Total current assets	340,351	43.7%	358,259	44.2%	5.3%
Total assets	778,070	100.0%	810,734	100.0%	4.2%



CONSOLIDATED BALANCE SHEET AS AT 31 MARCH 2024

(in EUR thousands)	31 Dec 2023	% share	31 Mar 2024	% share	% change
EQUITY AND LIABILITIES					
Shareholders' equity					
Subscribed capital	213,600	27.5%	213,600	26.3%	0.0%
Capital gains	17,479	2.2%	17,169	2.1%	(1.8%)
Treasury shares	(6,929)	(0.9%)	(7,945)	(1.0%)	14.7%
Reserves	172,144	22.1%	171,928	21.2%	(0.1%)
Retained earnings / (accumulated losses)	168,056	21.6%	191,486	23.6%	13.9%
Attributable to equity holders of the parent	564,350	72.5%	586,238	72.3%	3.9%
Non-controlling interests	10,642	1.4%	10,311	1.3%	(3.1%)
Total shareholders' equity	574,992	73.9%	596,549	73.6%	3.7%
Non-current liabilities					
Borrowings	534	0.1%	407	0.1%	(23.8%)
Lease liabilities	8,137	1.0%	12,419	1.5%	52.6%
Non-current provisions for employee benefits	7,482	1.0%	7,414	0.9%	(0.9%)
Other non-current provisions	5,068	0.7%	5,065	0.6%	(0.1%)
Other non-current liabilities	2,427	0.3%	2,385	0.3%	(1.7%)
Deferred tax liability	4,352	0.6%	4,320	0.5%	(0.7%)
Total non-current liabilities	28,000	3.6%	32,010	3.9%	14.3%
Current liabilities					
Trade and other payables	117,091	15.0%	121,622	15.0%	3.9%
Income tax payable	1,845	0.2%	3,812	0.5%	106.6%
Financial liabilities at fair value through profit and loss	9	0.0%	34	0.0%	277.8%
Borrowings	43,507	5.6%	43,240	5.3%	(0.6%)
Lease liabilities	5,254	0.7%	5,844	0.7%	11.2%
Current provisions for employee benefits	7,192	0.9%	7,444	0.9%	3.5%
Other current provisions	180	0.0%	179	0.0%	(0.6%)
Total current liabilities	175,078	22.5%	182,175	22.5%	4.1%
Total liabilities	203,078	26.1%	214,185	26.4%	5.5%
Total equity and liabilities	778,070	100.0%	810,734	100.0%	4.2%



CONSOLIDATED CASH FLOW STATEMENT IN 1 - 3 2024

(in EUR thousands)	1 - 3 2023	1 - 3 2024	%change
Profit before tax	19,139	29,204	52.6%
Depreciation and amortization	7,864	8,351	6.2%
Reversal of impairment of given loans and interests	(1)	(1)	0.0%
Reversal of impairment of assets held for sale	0	(4)	(100.0%)
Remeasurement of financial instruments at fair value	10	84	740.0%
Share based payment transactions	126	114	(9.5%)
Profit on sale and disposal of non-current assets	(117)	7	106.0%
Profit on sale of assets held for sale	0	(53)	(100.0%)
Adjustment for impairment losses of trade and other receivables	77	(109)	(241.6%)
Increase in provisions	397	259	(34.8%)
Interest income	(90)	(312)	(246.7%)
Interest expenses	362	492	35.9%
Effect of changes in foreign exchange rates	284	(222)	(178.2%)
Total adjustments	8,912	8,606	(3.4%)
Changes in working capital:			
(Increase) / Decrease in inventories	1,179	(4,667)	(495.8%)
Decrease / (Increase) in trade receivables	(6,687)	(9,643)	(44.2%)
Increase in trade payables	10,440	4,148	(60.3%)
Cash generated from operations	32,983	27,648	(16.2%)
Income tax paid	(1,707)	(975)	42.9%
Interest paid	(355)	(494)	(39.2%)
Net cash from operating activities	30,921	26,179	(15.3%)



CONSOLIDATED CASH FLOW STATEMENT IN 1 - 3 2024

(in EUR thousands)	1 - 3 2023	1 - 3 2024	%change
Cash flow from investing activities			
Purchase of property, plant, equipment and intangibles	(11,767)	(19,092)	(62.3%)
Proceeds from investing in marketable securities	0	8,000	100.0%
Proceeds from sale of property, plant, equipment and intangibles	165	90	(45.5%)
Proceeds from sale of assets held for sale	0	53	100.0%
Loans given	0	(88)	(100.0%)
Repayment of loans receivable	1	1	0.0%
Interest received	90	269	198.9%
Net cash from investing activities	(11,511)	(10,767)	6.5%
Cash flow from financing activities			
Dividend pay-out to minority shareholders	0	(895)	(100.0%)
Dividend pay-out	(4)	(7)	(75.0%)
Purchase of treasury shares	(1,543)	(1,016)	34.2%
Sale of treasury shares	109	0	(100.0%)
Proceeds from borrowings	39,886	1	(100.0%)
Repayment of borrowings	(36,680)	(287)	99.2%
Repayment of lease	(1,688)	(1,721)	(2.0%)
Net cash from financing activities	80	(3,925)	n/a
Net (decrease) / increase of cash and cash equivalents	19,490	11,487	(41.1%)
Cash and cash equivalents at beginning of the year	21,913	42,528	94.1%
Cash and cash equivalents at the end of year	41,403	54,015	30.5%



CONSOLIDATED STATEMENT OF CHANGES IN EQUITY IN 1 - 3 2024

(in EUR thousands)	Subscribed capital	Capital gains	Treasury shares	Other reserves	Retained earnings/accumulated loss	Total	Non-controlling interests	Total
As at 1 January 2023	207,897	24,780	(5,634)	163,898	128,241	519,182	9,424	528,606
Comprehensive income	-	-	-	-	-	-	-	-
Profit for the year	-	-	-	-	66,362	66,362	1,218	67,580
Foreign exchange differences	-	-	-	5	-	5	-	5
Actuarial losses (net of deferred tax)	-	-	-	86	-	86	-	86
Other comprehensive income	-	-	-	91	-	91	-	91
Total comprehensive income	-	-	-	91	66,362	66,453	1,218	67,671
<i>Transactions with owners recognized directly in equity</i>	-	-	-	-	-	-	-	-
Allocation from retained earnings	-	-	-	8,155	(8,155)	-	-	-
Additional acquisition of minority interests	-	-	-	-	-	-	-	-
Exercise of options	-	(2,430)	3,955	-	187	1,712	-	1,712
Fair value of share-based payment transactions	-	832	-	-	-	832	-	832
Purchase of treasury shares	-	-	(5,250)	-	-	(5,250)	-	(5,250)
Dividends paid	-	-	-	-	(18,579)	(18,579)	-	(18,579)
Adjustment of Issued Capital and Shares - EUR	5,703	(5,703)	-	-	-	-	-	-
Total transactions with owners recognized directly in equity	5,703	(7,301)	(1,295)	8,155	(26,547)	(21,285)	-	(21,285)
As at 31 December 2023	213,600	17,479	(6,929)	172,144	168,056	564,350	10,642	574,992
<i>Comprehensive income</i>	-	-	-	-	-	-	-	-
Profit for the year	-	-	-	-	23,454	23,454	564	24,018
Foreign exchange differences	-	-	-	(216)	-	(216)	-	(216)
Actuarial losses (net of deferred tax)	-	-	-	-	-	-	-	-
Other comprehensive income	-	-	-	(216)	-	(216)	-	(216)
Total comprehensive income	-	-	-	(216)	23,454	23,238	564	23,802
<i>Transactions with owners recognized directly in equity</i>	-	-	-	-	-	-	-	-
Allocation from retained earnings	-	-	-	-	-	-	-	-
Exercise of options	-	(424)	-	-	(24)	(448)	-	(448)
Fair value of share-based payment transactions	-	114	-	-	-	114	-	114
Purchase of treasury shares	-	-	(1,016)	-	-	(1,016)	-	(1,016)
Dividends paid	-	-	-	-	-	-	-	-
Total transactions with owners recognized directly in equity	-	(310)	(1,016)	-	(24)	(1,350)	(895)	(2,245)
As at 31 March 2024	213,600	17,169	(7,945)	171,928	191,486	586,238	10,311	596,549

NOTES TO THE FINANCIAL STATEMENTS

In 1 - 3 2024 period there were no changes in accounting policies.

The audited Annual report of the Podravka Group for 2023 are available at:

<https://www.podravka.com/investors/financial-reports/>

IMPLICATIONS OF THE RUSSIAN-UKRAINIAN CRISIS ON THE PODRAVKA GROUP'S OPERATIONS

The Russian market is of great importance for the Pharmaceuticals segment in terms of total sales revenues but also profitability, while in the Food segment the Russian market is not so significant in terms of total sales revenues or in terms of profitability. Management of Podravka Inc. continuously considers all risks associated with the Russian-Ukrainian conflict and assesses that these risks do not threaten Podravka Group's operations stability



Koprivnica, April 22th 2024

STATEMENT FROM EXECUTIVES RESPONSIBLE FOR PREPARING FINANCIAL STATEMENTS

According to our best knowledge consolidated unaudited financial statements of Podravka Group for the period 1 - 3 2024 have been prepared in compliance with the Accounting Act of the Republic of Croatia and International Financial Reporting Standards (IFRS) and provide an overall and true presentation of assets, liabilities, profit and loss, financial position and business operations of Podravka Group and all subsidiary companies involved in the consolidation.

Director of Corporate Financial Statements,
Deputy Corporate Accounting Director:
Julijana Artner Kukec



Board Member:
Davor Doko



Podravka 
PREHRAMBENA INDUSTRIJA D.D.
KOPRIVNICA 173



CONTACT

Podravka Inc.
Ante Starčevića 32, 48 000 Koprivnica
www.podravka.hr

Investor Relations
e-mail: ir@podravka.hr

